Analysts Set Medtronic PLC (NYSE:MDT) Target Price at $103.92

Shares of Medtronic PLC (NYSE:MDT) have earned a consensus rating of “Moderate Buy” from the twenty-eight research firms that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $103.92.

A number of equities research analysts have recently weighed in on the company. UBS Group lifted their price target on Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a report on Wednesday, September 2nd. Mizuho set a $115.00 target price on Medtronic in a research report on Wednesday, September 2nd. Rothschild & Co Redburn cut their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Finally, Bank of America lifted their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of MDT. Wellington Altus USA Inc. increased its stake in shares of Medtronic by 18.1% during the second quarter. Wellington Altus USA Inc. now owns 2,294 shares of the medical technology company’s stock valued at $199,000 after acquiring an additional 351 shares during the period. Bullseye Investment Management LLC acquired a new stake in Medtronic in the second quarter worth approximately $45,000. Keystone Financial Planning Inc. acquired a new stake in Medtronic in the second quarter worth approximately $9,889,000. Core Capital Management & Research inc. bought a new position in Medtronic during the 2nd quarter valued at $33,000. Finally, Tidal Investments LLC boosted its stake in Medtronic by 17.5% during the 2nd quarter. Tidal Investments LLC now owns 290,007 shares of the medical technology company’s stock valued at $22,687,000 after purchasing an additional 43,207 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its outlook again as demand for cardiovascular and heart devices continues to climb. Analysts also highlighted market-share gains in electrophysiology and improving momentum across several key franchises, supporting expectations for sustained revenue growth. Medtronic Raises its Outlook Again as Heart Device Demand Keeps Climbing BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system in the United States. The approval broadens Hugo’s instrument offering and could help Medtronic win additional robotic-surgery procedures and expand the platform’s long-term revenue base. Medtronic Announces FDA Clearance for LigaSure RAS Maryland Instrument
• Positive Sentiment: Coverage of Hugo’s expanding applications presents the surgical-robotics platform as a potential growth engine. Broader clinical use and a larger instrument ecosystem could diversify Medtronic beyond its established device franchises. Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
• Positive Sentiment: Medtronic’s latest earnings commentary pointed to broad-based growth momentum, complementing its previously reported earnings and revenue beats and year-over-year revenue growth. Medtronic Earnings Call Signals Broad-Based Growth Momentum
• Neutral Sentiment: Medtronic launched a share-exchange offer covering up to approximately 225.4 million newly issued shares as part of its planned diabetes-business spin-off. The transaction may sharpen the company’s strategic focus, although investors will monitor dilution, execution and the final ownership structure. Medtronic Advances Diabetes Spin-Off with Share Exchange
• Neutral Sentiment: Medtronic appointed former ReCor Medical CEO Lara Barghout to lead its Interventional Cardiology Therapies business, adding specialized experience in renal denervation and cardiovascular technology. Recor Medical Former CEO Joins Medtronic
• Negative Sentiment: Executive Vice President Harry Kiil sold 1,483 shares, worth about $139,000. The sale was relatively small and he retained a substantial position, limiting its significance, but insider selling can weigh modestly on sentiment.

Medtronic Stock Up 0.3%

MDT stock opened at $92.87 on Tuesday. The stock has a market cap of $118.80 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The firm’s 50-day simple moving average is $88.75 and its 200 day simple moving average is $84.98. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period in the previous year, the business posted $1.26 EPS. Medtronic’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts predict that Medtronic will post 5.97 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.